Clinical trial
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally…
NCT00492830 · Tracon Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00492830 |
|---|---|
| Title | Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors |
| Official title | A Phase 1, Open-label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors |
| Lead sponsor | Tracon Pharmaceuticals Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | TRC093 recombinant humanized IgG1k monoclonal antibody |
| Enrollment | 19 |
| Start date | Jun 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jun 27, 2007 |
| Last update posted | Feb 5, 2010 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: